An intellectually active lifestyle—in other words, the so-called cognitive reserve—has a protective effect on the progression and severity of the symptoms of motor, cognitive and psychiatric ...

Qure N.V. QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval ...

UniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...

An intellectually active lifestyle - in other words, the so-called cognitive reserve - has a protective effect on the ...

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...

The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.

The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...

Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...

Common symptoms of Huntington's include uncontrolled movements like jerking and twitching, loss of coordination, difficulty ...

Novartis will be gaining exclusive global rights to PTC Therapeutics’ mid-stage Huntington’s disease (HD) programme in a deal ...

Qure has reached an agreement with the U.S. Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130, its gene therapy treatment aimed at Huntington’s disease.

A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa Health Care researchers.